Challenges of drug development during the COVID‐19 pandemic: Key considerations for clinical trial designs | Zendy

Shi Jun | Zendy; Xiao Yubo | Zendy; Zhang Yiting | Zendy; Geng Donghao | Zendy; Cong Danhua | Zendy; Shi Kevin X. | Zendy; Knapp Richard J. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Challenges of drug development during the COVID‐19 pandemic: Key considerations for clinical trial designs

Author(s) -

Shi Jun,

Xiao Yubo,

Zhang Yiting,

Geng Donghao,

Cong Danhua,

Shi Kevin X.,

Knapp Richard J.

Publication year - 2021

Publication title -

british journal of clinical pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.216

H-Index - 146

eISSN - 1365-2125

pISSN - 0306-5251

DOI - 10.1111/bcp.14629

Subject(s) - covid-19 , pandemic , drug development , key (lock) , clinical trial , drug , medicine , intensive care medicine , virology , computer science , pharmacology , computer security , infectious disease (medical specialty) , outbreak , disease

There is an urgent need for targeted and effective COVID‐19 treatments. Several medications, including hydroxychloroquine, remdesivir, lopinavir–ritonavir, favipiravir, tocilizumab and others have been identified as potential treatments for COVID‐19. Bringing these repurposed medications to the public for COVID‐19 requires robust and high‐quality clinical trials that must be conducted under extremely challenging pandemic conditions. This article reviews translational science principles and strategies for conducting clinical trials in a pandemic and evaluates recent trials for different drug candidates. We hope that this knowledge will help focus efforts during this crisis and lead to the expedited development and approval of COVID‐19 therapies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research